Kasabach Merritt Syndrome C0221025
A rare disorder in infants where a vascular tumor traps platelets, causing bleeding and clotting problems. Treatment involves managing the tumor and addressing blood abnormalities, often requiring specialized care.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Bleeding tendency
High-output heart failure
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Vascular tumor enlargement
(hematologic)Anemia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Systemic corticosteroids as first-line therapy
Corticosteroids are the primary medical treatment to reduce vascular tumor proliferation and improve thrombocytopenia by decreasing endothelial growth factor production.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Embolization of hemangioma
Catheter-based embolization occludes blood supply to the vascular tumor, reducing its size and improving coagulopathy, particularly useful when lesion is surgically inaccessible.
Additional treatment options
Second-line pharmacotherapy (sirolimus or vincristine)
mTOR inhibitors like sirolimus or vincristine may be used when corticosteroids fail or are contraindicated, targeting different pathways involved in vascular proliferation.
medicationSurgical resection of hemangioma
Complete surgical excision may be curative when lesion is localized and accessible, though timing must consider coagulopathy and potential blood loss.
surgicalCoagulation parameter monitoring
Regular monitoring of platelet count, fibrinogen, D-dimer, and PT/INR to assess severity of consumptive coagulopathy and guide treatment intensity.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Kasabach Merritt Syndrome C0221025?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Kasabach Merritt Syndrome C0221025. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy